HTGF | High-Tech Gruenderfonds
High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Medical
mo:re
Seed Round in 2025
Mo:re specializes in developing a three-dimensional cell robotic platform designed to automate medical research. Its platform aims to standardize cell culture workflows for drug development, enabling researchers to scale up experiments while maintaining traceability and quality.
Hema.to
Seed Round in 2025
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Avelios Medical
Series A in 2025
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.
Lindis Blood Care
Venture Round in 2024
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Refoxy Pharma
Seed Round in 2024
Refoxy Pharma develops therapeutic medicines aimed at treating age-related diseases and enhancing healthy longevity. The company conducts research on proteins that regulate multiple genes involved in stress resistance and metabolism and develops novel modulators of a central stress response pathway to influence aging through genetics, with the goal of extending the years of healthy living.
Doctorflix
Seed Round in 2024
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.
SRTD Biotech
Seed Round in 2024
SRTD Biotech is a biotechnology company specializing in RNA-based therapies. It develops a pro-drug platform targeting various diseases, including cancer, viral infections, and genetic disorders. The company's approach involves selectively delivering RNAs to patients using techniques such as RNAi interference, mRNA, and fusogenic liposomes for organ-specific targeting, aiming to treat previously incurable conditions.
Mediaire
Venture Round in 2024
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Aignostics
Series B in 2024
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
Lymphatica Medtech
Series B in 2024
Lymphatica Medtech SA is a Swiss company that specializes in the design and manufacture of medical devices aimed at treating lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed innovative solutions such as the LymphoDrain system, which includes an active implantable lymphatic bypass that integrates a magnetically controlled micropump and subcutaneous catheters. This technology is designed to re-establish lymphatic circulation by internally draining lymphatic fluid from multiple points in the affected limb, providing a minimally invasive remedy for patients suffering from lymphedema. Lymphatica Medtech's commitment to advancing treatment options in this field reflects its focus on improving patient outcomes through cutting-edge medical technology.
BIOVOX
Seed Round in 2024
BIOVOX develops sustainable plastic materials tailored for healthcare applications. Their compounds are renewable, degradable, recyclable, and offer rigidity, surface hardness, and transparency, enabling medical manufacturers to reduce environmental impact while maintaining high safety standards.
IRUBIS
Seed Round in 2024
Founded in Munich, Germany in 2017, IRUBIS specializes in manufacturing Mid-Infrared (MIR) spectrometers and Attenuated Total Reflection (ATR) crystals. The company combines semiconductor technology with infrared spectroscopy to develop devices for analyzing protein-based drugs. IRUBIS offers a real-time bioprocess monitoring system using MIR spectroscopy, which measures glucose and lactate online without contamination risk. They also provide ATR crystals and accessory solutions.
HepaRegenix
Series C in 2024
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
SciRhom
Series A in 2024
SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.
Tubulis
Series B in 2024
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
RAYDIAX
Seed Round in 2023
RAYDIAX is a manufacturer of advanced therapy-assist computed tomography (CT) systems aimed at enhancing the quality of minimally invasive medical interventions, particularly for tumor treatments. The company develops imaging solutions that integrate a navigation system with both 2D and 3D X-ray live imaging, enabling healthcare providers to perform procedures with greater safety and efficiency. RAYDIAX's technology is designed to reduce the risk of postoperative complications, ultimately resulting in shorter hospital stays and quicker recovery times for patients. Through its innovative approach, RAYDIAX seeks to improve outcomes for both patients and clinicians in the realm of cancer therapy.
Inovedis
Series A in 2023
Inovedis specializes in innovative medical technologies aimed at optimizing patient care while reducing time and costs within the healthcare sector. The company develops advanced surgical devices, such as its flagship product designed for treating shoulder injuries, which leverages science-based technology to enable anatomical reconstruction of physiological tendon-bone connections.
Kranus Health
Series A in 2023
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Doctorflix
Seed Round in 2023
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.
smartbax
Seed Round in 2023
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Hema.to
Seed Round in 2023
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Dualyx
Series A in 2023
Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.
Nia Health
Seed Round in 2023
Nia Health develops digital health applications focused on dermatological conditions like eczema and psoriasis. Its AI-powered app provides personalized support and relief, aiming to improve patient outcomes through innovative digital solutions.
Phialogics
Pre Seed Round in 2023
Phialogics is a biotechnology company focused on developing innovative biologics to regulate the immune response in both acute and chronic inflammation. Its platform enables the creation of engineered antibodies and cell-type-specific immune checkpoint activators, targeting autoimmune diseases such as lupus, type 1 diabetes, and rheumatoid arthritis.
Mosanna Therapeutics
Seed Round in 2023
Mosanna Therapeutics is a biotechnology company based in Basel that focuses on improving patient outcomes and quality of life for individuals with high unmet medical needs. The company employs a precision medicine approach, specializing in the development of medicinal nasal sprays. Mosanna carefully selects innovative medicines for further development and collaborates with leading contract research organizations to ensure expertise in specialized fields. This strategy enables hospitals and doctors to effectively treat patients suffering from various diseases.
Mbiomics
Series A in 2023
Mbiomics is a biotechnology company focused on transforming microbiome research, diagnostics, and therapeutics. The firm operates a high-throughput, low-cost platform designed for dynamic and real-time analysis and quantification of the human gut microbiome. This technology enables precise diagnostics and targeted therapies, aiming to enhance patients' lives through innovative approaches to health management.
hbox
Seed Round in 2023
HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.
Refined Laser Systems
Seed Round in 2023
Refined Laser Systems is a specialized manufacturer of biophotonics devices, focusing on stain-free tissue diagnostics using its proprietary fiber-based tunable picosecond laser technology. The company's innovative laser systems enable rapid and reliable diagnoses, significantly reducing the time required compared to traditional methods.
PraxisEins.
Pre Seed Round in 2023
PraxisEins is a healthcare startup focused on enhancing outpatient care through innovative technology. The company develops a software-enabled platform that assists physicians in digitizing their processes, ultimately aimed at improving patient care and alleviating administrative burdens. By leveraging modern technology, PraxisEins enables doctors to conduct same-day consultations with patients, addressing the supply vacuum in outpatient services. Through its solutions, the company seeks to streamline workflows for healthcare providers and enhance the overall efficiency of outpatient care.
FundaMental Pharma
Seed Round in 2022
FundaMental Pharma is a neuroscience company developing novel drugs targeting neurodegeneration. Its portfolio focuses on preclinical stage therapies designed to uncouple the physiological function of glutamate-gated NMDA receptors from their toxic effects, aiming to stop neurodegeneration and improve brain health.
neotiv
Seed Round in 2022
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.
IRUBIS
Seed Round in 2022
Founded in Munich, Germany in 2017, IRUBIS specializes in manufacturing Mid-Infrared (MIR) spectrometers and Attenuated Total Reflection (ATR) crystals. The company combines semiconductor technology with infrared spectroscopy to develop devices for analyzing protein-based drugs. IRUBIS offers a real-time bioprocess monitoring system using MIR spectroscopy, which measures glucose and lactate online without contamination risk. They also provide ATR crystals and accessory solutions.
Kupando
Series A in 2022
Kupando is a biopharmaceutical company focused on developing immunostimulatory agents targeting toll-like receptors. Its mission is to create affordable immunotherapy options for cancer patients and prevent infectious diseases.
Aignostics
Series A in 2022
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
Kranus Health
Series A in 2022
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Noscendo
Venture Round in 2022
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.
Tubulis
Series B in 2022
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Lindis Blood Care
Venture Round in 2022
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Newsenselab (M-sense)
Seed Round in 2021
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Avelios Medical
Seed Round in 2021
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.
Abalos Therapeutics
Series A in 2021
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.
Cardior Pharmaceuticals
Series B in 2021
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
PreComb
Seed Round in 2021
PreComb develops advanced technologies to adapt cancer therapies to individual patients, aiming to enhance treatment success rates and improve patient outcomes.
GeneQuine Biotherapeutics
Series A in 2021
Founded in 2011, GeneQuine Biotherapeutics specializes in designing and developing gene therapies for clients. Its primary focus is on treating osteoarthritis through innovative products such as GQ-201, GQ-202, and GQ-203.
Kranus Health
Seed Round in 2021
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Mediaire
Seed Round in 2020
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Lymphatica Medtech
Series A in 2020
Lymphatica Medtech SA is a Swiss company that specializes in the design and manufacture of medical devices aimed at treating lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed innovative solutions such as the LymphoDrain system, which includes an active implantable lymphatic bypass that integrates a magnetically controlled micropump and subcutaneous catheters. This technology is designed to re-establish lymphatic circulation by internally draining lymphatic fluid from multiple points in the affected limb, providing a minimally invasive remedy for patients suffering from lymphedema. Lymphatica Medtech's commitment to advancing treatment options in this field reflects its focus on improving patient outcomes through cutting-edge medical technology.
Synendos Therapeutics
Series A in 2020
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.
heartbeat medical
Series A in 2020
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Aignostics
Seed Round in 2020
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
stimOS
Series A in 2020
stimOS GmbH is a biotechnology company based in Constance, Germany, founded in 2015. The company specializes in developing innovative drug delivery biochemical procedures aimed at enhancing bone formation, inflammation reduction, and healing processes. stimOS focuses on refining, functionalizing, and activating implant materials, transforming them into interfaces that closely mimic natural bone. By providing advanced technologies and procedures, stimOS serves as a supplier and service provider to implant manufacturers, facilitating the development of improved implant surfaces. The company's solutions are designed to promote early and healthy bone integration, thereby enabling faster recovery and improved outcomes for patients undergoing surgical procedures.
Tubulis
Series A in 2020
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Loewi
Seed Round in 2020
Loewi GmbH, founded in 2019 and based in Munich, Germany, operates an online platform specializing in non-pharmacy medical products, including medical self-tests and health products. As a scientific spin-off from the Technical University of Munich, the company aims to make personalized health and nutrition accessible to a wider audience. Loewi emphasizes a healthy and active lifestyle, focusing on data-driven personalization derived from evidence-based methods utilized in competitive sports over the past twelve years. The company offers personalized diet recommendations and supplements tailored to individual test results and health needs, promoting the analysis of nutrient requirements to help customers achieve their full potential. Loewi's commitment to integrating science and technology into its offerings is complemented by collaborations with leading universities and research institutions, reinforcing its role in advancing the industry.
Kumovis
Series A in 2020
Kumovis is a medical technology company that specializes in developing a 3D printing system designed for both industrial and medical applications. The company focuses on the processing of high-performance polymers to create patient-customized implants. By integrating clean room technology into its 3D printing solutions, Kumovis enables hospitals to perform medical operations more conveniently and effectively, enhancing the overall quality of care.
Noscendo
Series A in 2020
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.
HepaRegenix
Series B in 2020
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
Lindis Blood Care
Venture Round in 2019
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Verovaccines
Seed Round in 2019
VEROVACCiNES GmbH is a biopharmaceutical company based in Halle, Germany, founded in 2017 as a spin-off from the Martin Luther University Halle-Wittenberg. The company specializes in developing innovative vaccine solutions to protect animals from infectious diseases, utilizing a unique yeast-based technology to create subunit marker vaccines. This approach has been validated through proof-of-concept studies demonstrating protection across various animal species against several viral diseases. VEROVACCiNES has acquired intellectual property, branding, and expertise from a previous project funded by the BMBF GO-Bio program and is eligible for additional funding. The company actively collaborates with veterinary pharmaceutical firms, universities, and research institutions to enhance its vaccine development efforts.
Newsenselab (M-sense)
Seed Round in 2019
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Draupnir Bio
Seed Round in 2019
Draupnir Bio is a biotechnology company focused on developing a new class of cholesterol-lowering medicines to prevent heart blood clots more effectively than existing therapies. The company pursues a platform that maps and leverages the glycome to build heparan sulfate glycomimetics, enabling synthesis, screening, and selection of potent, specific drug candidates for cardiovascular, inflammatory, and infectious diseases. Leveraging its technology, the firm aims to develop protein degraders that target extracellular disease proteins, potentially broadening therapeutic reach across unmet medical needs. The approach seeks to offer convenient treatment options that could reduce reliance on traditional injectables. Through its glycome-based platform, Draupnir Bio targets modalities beyond small molecules, with a focus on extracellular targets and biologics-compatible strategies to improve patient outcomes.
Abalos Therapeutics
Series A in 2019
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.
Vacis
Venture Round in 2019
Vacis specializes in tissue engineering technology for creating body-own blood vessels. Its platform induces the body to form functional blood vessels, offering novel therapeutic options and reducing complications associated with prosthetic vascular grafts.
Tacalyx
Seed Round in 2019
Tacalyx GmbH is an oncology company based in Berlin, Germany, dedicated to the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies for cancer treatment. As a spin-off from the Max-Planck-Institute of Colloids and Interfaces, the company leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures serve as novel targets for cancer therapies, addressing the tumor-specific expression of TACAs that results from aberrant glycosylation, which is linked to cancer progression, including metastasis and immune system suppression. Tacalyx aims to develop innovative therapeutics that enhance the effectiveness of immunotherapies by triggering robust anti-cancer responses through the synthesis and identification of antibodies targeting these carbohydrate antigens.
Belyntic
Seed Round in 2019
Belyntic is a biotechnology company focused on developing innovative vaccines aimed at preventing viral diseases, bacterial infections, and cancer. The company has created a cutting-edge platform that utilizes self-adjuvant synthetic long peptides to effectively induce cellular immunity. By offering ready-to-use research kit packages and engineered vaccines, Belyntic activates T-cell immune responses, providing significant potential for advancing protective measures against various health threats. Additionally, the company integrates artificial intelligence to enhance its vaccine development, allowing for the incorporation of pathogen-specific epitopes into a self-adjuvant nano vaccine structure. This approach facilitates research, development, and production of novel peptide therapeutics, contributing to healthier lives.
Pantherna Therapeutics
Seed Round in 2019
Pantherna Therapeutics GmbH is a biopharmaceutical company based in Hennigsdorf, Germany, founded in 2017. The company specializes in developing innovative mRNA therapeutics aimed at treating acute respiratory distress syndrome (ARDS) and vascular diseases. Pantherna Therapeutics utilizes a unique technology platform based on advanced nanoparticles that facilitate the delivery and expression of therapeutic mRNA drugs specifically in the endothelium. This approach aims to prevent the formation of edema and lung tissue injury associated with ARDS while also enabling the restoration of endothelial cell function.
miRdetect
Seed Round in 2019
miRdetect GmbH is a German biotechnology company based in Bremen, established in 2016. The company develops and markets in-vitro diagnostic tests, focusing on the early detection and diagnosis of cancer. Among its products is the miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect employs advanced molecular biological techniques that enable the precise identification of minute quantities of nucleic acids, facilitating accurate cancer diagnosis. In addition to its current offerings, the company is actively engaged in research and development to create new diagnostic tests aimed at improving cancer detection capabilities.
NAVAN Technologies
Seed Round in 2019
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company specializes in developing and commercializing its proprietary NanoStraw platform technology, which provides a direct and gentle means of accessing the cytosol of cells. This innovative platform addresses a significant challenge in the field of cell and gene therapies by enabling the efficient delivery of various cargoes into difficult-to-transfect cells without causing disruption. NAVAN's technology aims to enhance the capabilities of researchers and improve the effectiveness of therapeutic applications in biotechnology.
Mediaire
Seed Round in 2019
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Cytena
Series A in 2019
Cytena develops a laboratory device for separating and printing single cells. Its core product, the cy-Clone, encapsulates cells in droplets for gentle delivery onto substrates, ensuring high cell viability and minimal risk of cross-contamination. This technology aids in drug development, cancer research, and stem cell analysis.
denovoMATRIX
Seed Round in 2018
Founded in 2018, denovoMATRIX develops biomimetic coatings for stem cell culture. Its products include screenMATRIX, which enhances cell adhesion and differentiation, and myMATRIX, a custom-coated tissue cultureware for serum-free media. These are used in stem cell research, tissue models, and cell-based therapies.
Amal Therapeutics
Series B in 2018
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
Kumovis
Seed Round in 2018
Kumovis is a medical technology company that specializes in developing a 3D printing system designed for both industrial and medical applications. The company focuses on the processing of high-performance polymers to create patient-customized implants. By integrating clean room technology into its 3D printing solutions, Kumovis enables hospitals to perform medical operations more conveniently and effectively, enhancing the overall quality of care.
Adivo
Seed Round in 2018
Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that focuses on developing species-specific therapeutic antibodies for companion animals, particularly dogs. The company aims to address serious diseases in pets while also exploring the potential for therapies applicable to other species. Adivo utilizes a new, fully synthetic, dog-specific drug library to isolate antibodies with optimal properties through phage display technology. The team at Adivo brings extensive experience from the development of human therapeutic antibodies, leveraging this expertise to innovate within the field of veterinary medicine. As a spin-off of MorphoSys AG, Adivo is positioned to advance therapeutic options for pets, contributing to improved health outcomes in companion animals.
Newsenselab (M-sense)
Venture Round in 2018
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
neotiv
Seed Round in 2018
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.
heartbeat medical
Venture Round in 2017
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
RIMASYS
Venture Round in 2017
RIMASYS is dedicated to advancing surgical education and medical technology research and development. The company focuses on creating realistic fractures in human specimens through a unique algorithm and device, which supports practical skill training for surgeons. By integrating digital learning, virtual reality, and 3D printing, RIMASYS aims to improve patient outcomes and enhance the quality of life for individuals requiring advanced therapies and operations. Their innovative approach facilitates collaboration among medical science, academia, and industry, fostering the development of better implants and surgical techniques.
Amal Therapeutics
Series B in 2017
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
stimOS
Seed Round in 2017
stimOS GmbH is a biotechnology company based in Constance, Germany, founded in 2015. The company specializes in developing innovative drug delivery biochemical procedures aimed at enhancing bone formation, inflammation reduction, and healing processes. stimOS focuses on refining, functionalizing, and activating implant materials, transforming them into interfaces that closely mimic natural bone. By providing advanced technologies and procedures, stimOS serves as a supplier and service provider to implant manufacturers, facilitating the development of improved implant surfaces. The company's solutions are designed to promote early and healthy bone integration, thereby enabling faster recovery and improved outcomes for patients undergoing surgical procedures.
Cardior Pharmaceuticals
Series A in 2017
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
KSK Diagnostics
Series A in 2017
KSK Diagnostics GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays. The company focuses on creating tests for the molecular diagnosis of infectious diseases and cancer, utilizing innovative isothermal amplification technology. These assays are designed to provide rapid results, allowing healthcare professionals to make timely diagnoses and coordinate treatment plans effectively, often within 30 minutes. In addition to its core diagnostic products, KSK Diagnostics offers customizable services for nucleic acid-based test development, including real-time PCR and RT-PCR, as well as verification, validation studies, and product enhancement services for other organizations. As a pioneering entity in its field, KSK Diagnostics is committed to advancing patient-oriented diagnostics.
SciRhom
Seed Round in 2017
SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.
HepaRegenix
Series A in 2016
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
AudioCure Pharma
Series A in 2016
AudioCure Pharma GmbH is a pharmaceutical company based in Berlin, Germany, specializing in the development of drugs for neurodegenerative diseases and hearing impairments. Founded in 2010 by Professor Hans Rommelspacher, the company has assembled a team of skilled scientists and executives, supported by a network of academic partners and strategic investors. AudioCure Pharma is located in a central area of Mitte, providing access to numerous high-tech companies and universities, including close ties with the Charité University. The company is focused on advancing its leading compound, AC102, which is in late-stage preclinical development for treating acute noise-induced hearing loss and has demonstrated preclinical proof of concept since 2016.
Newsenselab (M-sense)
Venture Round in 2016
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Rigontec
Series A in 2016
Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.
Thermosome
Seed Round in 2016
Thermosome GmbH is a biopharmaceutical company based in Planegg, Germany, specializing in the development of drug candidates utilizing a proprietary drug delivery technology. This platform, founded on research from the Max Planck Institute for Biophysical Chemistry, enables intravascular drug release, effectively targeting locally advanced solid tumors. Thermosome's lead product is a formulation of a chemotherapeutic compound currently in the final stages of pre-clinical development. The company's focus is on enhancing antitumor responses in cancer treatment, aiming to provide patients with more effective therapies that minimize side effects and expedite the initiation of treatment. Since its inception in late 2015, Thermosome has been dedicated to advancing innovative solutions in cancer care.
Amal Therapeutics
Series A in 2016
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
Abviris Deutschland
Seed Round in 2016
Abviris Deutschland GmbH is a German company founded in 2014, specializing in the development, manufacture, and marketing of in-vitro diagnostics and medical devices aimed at addressing oral cancer. Based in Ammersbek, the company focuses on utilizing immunologically active components, including a variety of antibodies targeting different types of human papilloma virus (HPV) and relevant antigens. One of its key products is PrevO-Check, an in-vitro diagnostic medical device designed for the screening of HPV-induced oral cavity cancer. Abviris Deutschland addresses the challenge of early detection, particularly since HPV infections often do not exhibit early symptoms, leading to late-stage diagnoses. The company's innovations aim to improve screening processes, especially in areas of the oral cavity that are not typically examined during standard dental visits.
heartbeat medical
Venture Round in 2016
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Bomedus
Series B in 2015
Bomedus is a Germany-based medical device company founded in 2011, focused on improving mobility for individuals suffering from chronic back pain. The company develops innovative devices that utilize an electro-therapeutic method to provide permanent and sustainable pain reduction. By non-invasively modulating pathologically altered neuronal impulses, Bomedus aims to enhance the quality of life for patients dealing with pain-related challenges.
Eyetronic Therapie
Venture Round in 2015
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.
Cytena
Seed Round in 2015
Cytena develops a laboratory device for separating and printing single cells. Its core product, the cy-Clone, encapsulates cells in droplets for gentle delivery onto substrates, ensuring high cell viability and minimal risk of cross-contamination. This technology aids in drug development, cancer research, and stem cell analysis.
Sonormed GmbH
Series A in 2015
Sonormed GmbH is a medical technology company based in Hamburg, Germany, established in 2012. It specializes in digital audiology, developing Tinnitracks, a web application designed for tinnitus therapy. This innovative platform allows users to filter and select music that aligns with neuroscientific principles for effective treatment of tinnitus. Additionally, Tinnitracks automatically assesses music files to evaluate their therapeutic potential, providing users with feedback on the suitability of specific tracks for their therapy.
Immunservice
Series C in 2015
Immunservice is a biotechnology company focused on research and development of biomimetic immune hormone therapies, particularly interleukin-2, for cancer, viral diseases, and related conditions. It translates natural immune hormone systems into therapeutic innovations, developing biomimetic interleukin drugs that aim to enhance immune response, treat orphan indications, and support clinical development. The company works on medicinal forms of interleukin-2 that target lung metastases and tumors, including Pulmoleukin, a natural biomimetic interleukin-2 drug designed to prevent suffocation in patients with lung tumors, and also explores applications in papillomavirus-related conditions and immune rejuvenation, as well as diagnostic and treatment insights across human and animal immunotherapy and human cell therapy. It engages in patent-related activities, biomimetic therapies, and clinical development to advance these therapies.
Rigontec
Series A in 2014
Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.
Medineering
Seed Round in 2014
Medineering is a medical technology company based in Munich, Germany, that focuses on developing and marketing innovative robotic systems for minimally invasive head surgery. Founded in 2014, the company offers a modular portfolio of surgical manipulators, enabling clinics and surgeons to select the level of automation and functionality that aligns with their surgical needs and budgetary considerations. Medineering's product line includes an intelligent positioning arm and compact, application-specific robots designed to assist surgeons in navigating complex anatomical regions. The company's mission is to enhance the capabilities of minimally invasive surgery through advanced robotic solutions tailored to specific surgical tasks and environments.
i3 Membrane
Seed Round in 2014
Founded in 2013, i3 Membrane specializes in manufacturing steel filter membranes primarily for life science markets. Its products are also used in medical and pharmaceutical sectors.
Desino
Series A in 2014
Desino is a Cologne, Germany-based company that specializes in developing adaptive wheelchairs designed to enhance mobility and comfort for users. The company focuses on integrating a dynamic seating system that promotes continuous motion of the spine and back muscles, mimicking the natural movement of walking. This innovative approach aims to alleviate back discomfort and improve overall well-being for individuals who spend extended periods seated. Additionally, Desino's wheelchairs feature a unique combination of classic handrails and effortless lever propulsion, facilitating long-distance travel and catering to the specific needs of each customer. Through its advancements in wheelchair design, Desino seeks to provide enhanced mobility solutions that prioritize user health and comfort.
microDimensions
Seed Round in 2014
microDimensions develops software solutions for processing, analyzing, and visualizing microscopic image data, primarily in biomedical fields. Its key products include Voloom (for automated 3D reconstruction), Zoom (for fast visualization of whole slide images), and anyslide/slidematch. These tools assist pharmaceutical, biotechnology, and pathology researchers with tasks like cell counting, tumor border computation, scoring, volume measurements, and finding regions in serial sections. microDimensions offers its products through distribution partners.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.